TP53 and neoplasm: In other words, the miR371a-3 cluster appears to retain its suitability as a GCT biomarker irrespective of the tumor’s TP53 status and, thus, also partially the level of cisplatin resistance [20,32,33,34,35,36,37,38,47,48,49].